{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Second-line+Chemotherapy&page=2",
    "query": {
      "intervention": "Second-line Chemotherapy",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 210,
    "total_pages": 21,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Second-line+Chemotherapy&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Second-line+Chemotherapy&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-01T00:27:43.009Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05733598",
      "title": "Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatocellular Carcinoma",
        "Biliary Tract Cancer"
      ],
      "interventions": [
        {
          "name": "RP2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Atezolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RP2 Monotherapy",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Replimune, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2024-08-01",
      "completion_date": "2028-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-02",
      "last_synced_at": "2026-10-01T00:27:43.009Z",
      "location_count": 12,
      "location_summary": "Beverly Hills, California • La Jolla, California • Miami, Florida + 9 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05733598"
    },
    {
      "nct_id": "NCT05712356",
      "title": "A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cholangiocarcinoma",
        "Gallbladder Cancer",
        "Gallbladder Carcinoma",
        "Intrahepatic Cholangiocarcinoma",
        "Extrahepatic Cholangiocarcinoma",
        "Bile Duct Cancer",
        "Gall Bladder Cancer",
        "Gall Bladder Carcinoma"
      ],
      "interventions": [
        {
          "name": "certepetide",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "FOLFOX regimen",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lisata Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2023-05-13",
      "completion_date": "2026-04-05",
      "has_results": true,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-10-01T00:27:43.009Z",
      "location_count": 19,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 15 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Merriam",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05712356"
    },
    {
      "nct_id": "NCT06076837",
      "title": "The Seven Trial: Exploiting the Unfolded Protein Response",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Cancer Metastatic",
        "Pancreatic Adenocarcinoma Metastatic"
      ],
      "interventions": [
        {
          "name": "Botensilimab",
          "type": "DRUG"
        },
        {
          "name": "Balstilimab",
          "type": "DRUG"
        },
        {
          "name": "Chloroquine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Celecoxib",
          "type": "DRUG"
        },
        {
          "name": "Nab paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "HonorHealth Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2025-01-09",
      "completion_date": "2025-12-22",
      "has_results": false,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-10-01T00:27:43.009Z",
      "location_count": 1,
      "location_summary": "Scottsdale, Arizona",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06076837"
    },
    {
      "nct_id": "NCT00813254",
      "title": "Cost Utility Analysis in Recurrent Ovarian Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Questionnaire",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 0,
      "start_date": "2008-12",
      "completion_date": "2011-01",
      "has_results": false,
      "last_update_posted_date": "2012-04-19",
      "last_synced_at": "2026-10-01T00:27:43.009Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00813254"
    },
    {
      "nct_id": "NCT04003636",
      "title": "Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Biliary Tract Carcinoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1069,
      "start_date": "2019-09-24",
      "completion_date": "2025-04-01",
      "has_results": true,
      "last_update_posted_date": "2026-03-24",
      "last_synced_at": "2026-10-01T00:27:43.009Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04003636"
    },
    {
      "nct_id": "NCT04552535",
      "title": "A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Squamous Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Second line (2L) afatinib",
          "type": "DRUG"
        },
        {
          "name": "Second line chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2020-05-08",
      "completion_date": "2020-05-18",
      "has_results": true,
      "last_update_posted_date": "2022-01-11",
      "last_synced_at": "2026-10-01T00:27:43.009Z",
      "location_count": 1,
      "location_summary": "Dublin, Ohio",
      "locations": [
        {
          "city": "Dublin",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04552535"
    },
    {
      "nct_id": "NCT05256290",
      "title": "Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Advanced Non-Small Cell Squamous Lung Cancer",
        "Metastatic Lung Non-Small Cell Carcinoma",
        "Metastatic Lung Cancer",
        "NSCLC",
        "Advanced Lung Carcinoma",
        "Epidermal Growth Factor Receptor C797S",
        "Epidermal Growth Factor Receptor G719X",
        "EGF-R Positive Non-Small Cell Lung Cancer",
        "EGFR-TKI Resistant Mutation"
      ],
      "interventions": [
        {
          "name": "silevertinib (BDTX-1535) monotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Black Diamond Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2022-03-31",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-10-01T00:27:43.009Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Huntington Beach, California + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05256290"
    },
    {
      "nct_id": "NCT00319969",
      "title": "Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Amrubicin",
          "type": "DRUG"
        },
        {
          "name": "Topotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 76,
      "start_date": "2006-04",
      "completion_date": "2009-01",
      "has_results": false,
      "last_update_posted_date": "2009-09-30",
      "last_synced_at": "2026-10-01T00:27:43.009Z",
      "location_count": 47,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 40 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00319969"
    },
    {
      "nct_id": "NCT05063552",
      "title": "Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",
        "Metastatic Head and Neck Squamous Cell Carcinoma",
        "Metastatic Hypopharyngeal Squamous Cell Carcinoma",
        "Metastatic Laryngeal Squamous Cell Carcinoma",
        "Metastatic Lip and Oral Cavity Carcinoma",
        "Metastatic Nasal Cavity Squamous Cell Carcinoma",
        "Metastatic Nasopharyngeal Squamous Cell Carcinoma",
        "Metastatic Pharyngeal Squamous Cell Carcinoma",
        "Metastatic Sinonasal Squamous Cell Carcinoma",
        "Recurrent Head and Neck Squamous Cell Carcinoma",
        "Recurrent Hypopharyngeal Squamous Cell Carcinoma",
        "Recurrent Laryngeal Squamous Cell Carcinoma",
        "Recurrent Lip and Oral Cavity Squamous Cell Carcinoma",
        "Recurrent Nasopharyngeal Squamous Cell Carcinoma",
        "Recurrent Pharyngeal Squamous Cell Carcinoma",
        "Recurrent Sinonasal Squamous Cell Carcinoma",
        "Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8",
        "Stage IV Hypopharyngeal Carcinoma AJCC v8",
        "Stage IV Laryngeal Cancer AJCC v8",
        "Stage IV Lip and Oral Cavity Cancer AJCC v8",
        "Stage IV Nasopharyngeal Carcinoma AJCC v8",
        "Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8",
        "Stage IV Sinonasal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 430,
      "start_date": "2023-03-13",
      "completion_date": "2027-12-15",
      "has_results": false,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-10-01T00:27:43.009Z",
      "location_count": 172,
      "location_summary": "Little Rock, Arkansas • Dublin, California • Emeryville, California + 135 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Dublin",
          "state": "California"
        },
        {
          "city": "Emeryville",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Martinez",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05063552"
    },
    {
      "nct_id": "NCT06788756",
      "title": "L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Acute Myeloid Leukaemia (AML)"
      ],
      "interventions": [
        {
          "name": "Placebo in combination with Cytarabine Injection",
          "type": "DRUG"
        },
        {
          "name": "Liposomal Annamycin Injection in combination with Cytarabine Injection",
          "type": "DRUG"
        },
        {
          "name": "Liposomal Annamycin for Injection in combination with Cytarabine Injection.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Moleculin Biotech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 312,
      "start_date": "2025-03-12",
      "completion_date": "2030-08",
      "has_results": false,
      "last_update_posted_date": "2026-08-05",
      "last_synced_at": "2026-10-01T00:27:43.009Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Miami, Florida • Augusta, Georgia + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Morristown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06788756"
    }
  ]
}